Financial Results
MDxHealth Provides Q3 2011 Business Update
MDxHealth SA issued its business update for the third quarter and for the nine months ended September 30, 2011. -Financial discipline continued to pay-off: cash burn (excluding the funds provided by the private placement of April 2011) and net loss were reduced by 25% and 12% in the first 9 months of 2011, respectively, compared to the same period in 2010. -MDxHealth established its own U.S.-based CLIA lab in Irvine, CA to prepare for projected sales of its Prostate ConfirmMDx test nationwide...
GenMark Diagnostics Reports Q3 2011 Results
GenMark Diagnostics Inc. reported financial results for the third quarter ended September 30, 2011. Revenues for the three months ended September 30, 2011 were $1.3 million compared with $684,000 during the third quarter of 2010. The 90% year-over-year increase in total revenue reflects an increase in the number of systems in the field, growth in the Company's test menu and a significant increase in the number of tests sold. Reagent revenues for the third quarter grew 83% year over year to $1.2...
Transgenomic Reports Q3 Financial Results
Transgenomic Inc. reported financial results for the three and nine months ended September 30, 2011. Total revenue for the third quarter 2011 was $8.3 million, an increase of 87% compared with $4.4 million for the same period of 2010. Revenues for the third quarter of 2011 included $4.1 million in sales related to the Clinical Laboratory Services business, $552,000 in revenue related to the Pharmacogenomics Services unit and $3.6 million in revenue related to the Diagnostic Tools unit. For the...
Gen-Probe Reports Financial Results for the Third Quarter of 2011
Gen-Probe Inc. has reported financial results for the third quarter of 2011, with total revenues of $139.1 million and non-GAAP earnings per share of $0.57. "Gen-Probe's non-GAAP financial results in the third quarter of 2011 were in line with our expectations," said Carl Hull, Gen-Probe's president and CEO, in a press release. "In addition, we are pleased with the progress of our two ongoing new product introductions, and excited that we are already launching our APTIMA HPV...
Thermo Fisher Scientific Establishes New Reporting Segment
Thermo Fisher Scientific Inc. has established a new financial reporting segment, called Specialty Diagnostics, following its acquisition of Phadia, a global leader in blood tests for the clinical diagnosis and monitoring of allergies and autoimmune diseases. As a result, Thermo Fisher's financial performance will be reported in three segments instead of two, effective with the company's third fiscal quarter of 2011. The new Specialty Diagnostics Segment will consist of five businesses:...
Luminex Reports Q2 2011 Results
Luminex Corp. announced financial results for the second quarter ended June 30, 2011. Financial and operating highlights include the following: -Consolidated second quarter revenue was $47.6 million, a 43% increase over the second quarter of 2010. -Second quarter 2011 consumable sales of $18.4 million, a 90% increase over the second quarter of 2010. -Second quarter 2011 shipments of 248 multiplexing analyzers that included 62 MAGPIX systems, resulting in cumulative life-to-date multiplexing...
Genomic Health Announces Q2 2011 Financial Results
Genomic Health Inc. reported financial results and business progress for the quarter ended June 30, 2011. Total revenue increased to $50.8 million in the second quarter of 2011, compared with $43.4 million in the second quarter of 2010. Product revenue was $50.5 million in the second quarter of 2011, an increase of 19%, compared with $42.5 million in the second quarter of 2010. Net income was $2.3 million in the second quarter of 2011, compared with net income of $0.9 million in the second...
Chembio Reports Q2 2011 Results
Chembio Diagnostics Inc. reported revenues and earnings for the quarter ended June 30, 2011. Total revenues were $3.61 million for the quarter ended June 30, 2011, which compares to total revenues of $3.75 million for the quarter ended June 30, 2010, a 3.6% decrease. The company recorded a net income of approximately $0.19 million, or less than $0.01 per share, for the quarter ended June 30, 2011, compared to a net income of approximately $0.62 million, or $0.01 per share, for the quarter ended...
Response Biomedical Announces First Quarter Results
Response Biomedical Corp. reported financial results for the first quarter ended March 31, 2011. Total revenues for the three-month period ended March 31, 2011 increased 59% to $2,470,560 compared to $1,549,479 for the same period last year. Operating expenses for the three-month period ended March 31, 2011 decreased 37% to $1,733,458 from $2,747,614 for the same period last year. Net loss decreased by 48% to $1,382,205 or $0.04 per share. As at March...
Chembio Reports 1st Quarter 2011 Results
Chembio Diagnostics Inc. reported revenues and earnings for the quarter ended March 31, 2011. Total revenues were $3.64 million for the quarter ended March 31, 2011, which compares to total revenues of $2.78 million for the quarter ended March 31, 2010, a 30.6% increase. The company recorded a net loss of approximately $0.14 million, or less than a $0.01 per share, for the quarter ended March 31, 2011, compared to a net loss of approximately $0.15 million, or less than $0.01 per share, for the...